Mayne Pays US$34 M for Rights to SuperGen Oncology
By Business Review Editor
Pharma Deals Review: Vol 2006 Issue 74 (Table of Contents)
Published: 6 Aug-2006
DOI: 10.3833/pdr.v2006.i74.477 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Mayne Pharma is to acquire the US rights to Nipent®, a chemotherapy agent for the treatment of hairy cell leukemia and SurfaceSafe® from SuperGen for US$34 M including approximately US$14 M upfront...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS